These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38357386)

  • 1. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
    Tighiouart M; Jiménez JL; Diniz MA; Rogatko A
    Braz J Biom; 2022 Dec; 40(4):453-468. PubMed ID: 38357386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
    Diniz MA; Kim S; Tighiouart M
    J Probab Stat; 2018; 2018():. PubMed ID: 30906326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
    Tighiouart M; Li Q; Piantadosi S; Rogatko A
    Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
    Tighiouart M; Piantadosi S; Rogatko A
    Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
    Diniz MA; Kim S; Tighiouart M
    Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.
    Jiménez JL; Kim S; Tighiouart M
    Biom J; 2020 Sep; 62(5):1300-1314. PubMed ID: 32150296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.
    Tighiouart M
    J R Stat Soc Ser C Appl Stat; 2019 Jan; 68(1):235-250. PubMed ID: 30745708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
    Wheeler GM; Sweeting MJ; Mander AP
    Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.
    Jiménez JL; Tighiouart M
    J R Stat Soc Ser C Appl Stat; 2022 Nov; 71(5):1996-2013. PubMed ID: 36779084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
    Pantoja K; Lanke S; Munafo A; Victor A; Habermehl C; Schueler A; Venkatakrishnan K; Girard P; Goteti K
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1371-1381. PubMed ID: 35852048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.